Advertisement
Research Article

Clinical, Epidemiologic, Histopathologic and Molecular Features of an Unexplained Dermopathy

  • Michele L. Pearson,

    Affiliation: Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Joseph V. Selby,

    Affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America

    X
  • Kenneth A. Katz,

    Affiliation: HIV, STD, and Hepatitis Branch, Health and Human Services Agency, County of San Diego, San Diego, California, United States of America

    X
  • Virginia Cantrell,

    Affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America

    X
  • Christopher R. Braden,

    Affiliation: Division of Food, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Monica E. Parise,

    Affiliation: Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Christopher D. Paddock,

    Affiliation: Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Michael R. Lewin-Smith,

    Affiliation: Environmental Pathology, Joint Pathology Center, Silver Spring, Maryland, United States of America

    X
  • Victor F. Kalasinsky,

    Affiliation: Office of Research & Development, United States Department of Veterans Affairs, Washington, District of Columbia, United States of America

    X
  • Felicia C. Goldstein,

    Affiliation: Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, United States of America

    X
  • Allen W. Hightower,

    Affiliation: Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Arthur Papier,

    Affiliation: Department of Dermatology, University of Rochester School of Medicine, Rochester, New York, United States of America

    X
  • Brian Lewis,

    Affiliation: Division of Health Studies, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, United States of America

    X
  • Sarita Motipara,

    Affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America

    X
  • Mark L. Eberhard mail,

    mle1@cdc.gov

    Affiliation: Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • for the Unexplained Dermopathy Study Team

    Additional membership of the Unexplained Dermopathy Study Team is provided in the Acknowledgments.

    X
  • Published: January 25, 2012
  • DOI: 10.1371/journal.pone.0029908

Reader Comments (24)

Post a new comment on this article

CDC & Actinomycosis

Posted by cynt on 23 Apr 2012 at 19:39 GMT

Perhaps someone can tell me how/where the CDC classifies agents of Actinomycosis (Anaerobic Actinomyces). I searched every possible classification I could think of to no avail. Surely, this important disease/ class of bacteria has not been overlooked.

No competing interests declared.